The New Blueprint for Vaccine Development - Top-Institutions - MDSpire

The New Blueprint for Vaccine Development

ReiThera’s leaders discuss platform technologies, scalable manufacturing, and the trust needed to strengthen global vaccine preparedness

  • March 12, 2026

  • 6 min

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

  • #1

    National Institute of Allergy and Infectious Diseases (NIAID)
    National Institute of Allergy and Infectious Diseases (NIAID)

    Bethesda, MD

    Key Differentiators

    • Vaccine Research
    • Immunology
    • Infectious Diseases

  • #2

    Pfizer Inc.
    Pfizer Inc.

    New York, NY

    Key Differentiators

    • Vaccine Manufacturing
    • Pharmaceutical Development

  • #3

    Moderna, Inc.
    Moderna, Inc.

    Cambridge, MA

    Key Differentiators

    • mRNA Vaccine Technology
    • Rapid Vaccine Development

  • #4

    ReiThera Srl
    ReiThera Srl

    Rome, Italy

    Key Differentiators

    • Viral Vector Vaccines
    • GMP Manufacturing

  • #5

    The Jenner Institute, University of Oxford
    The Jenner Institute, University of Oxford

    Oxford, United Kingdom

    Key Differentiators

    • Viral Vector Vaccines
    • Clinical Vaccine Trials

Original Source(s)

The New Blueprint for Vaccine Development

  • March 12, 2026

Related Content

High-Dose vs Standard-Dose Influenza Vaccines in Older Adults: A Meta-Analysis

HHS appeals ruling that stalled many of Kennedy’s vaccine policy changes

Self-administered digital vaccination decision-aids in primary care: A pilot study of COVID-19 vaccination in Atlanta, GA